DGX
Quest Diagnostics IncorporatedNYSEHealthcare$198.02+0.17%ClosedMarket Cap: $22.03B
As of 2026-04-06
Valuation
P/E (TTM)
22.21
PEG
1.60
P/B
3.07
P/S
2.00
EV/EBITDA
14.04
DCF Value
$221.12
FCF Yield
6.2%
Div Yield
1.6%
Margins & Returns
Gross Margin
33.2%
Operating Margin
14.1%
Net Margin
9.0%
ROE
13.9%
ROA
17.6%
ROIC
8.2%
Income Statement
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q4 2025 | $2.81B | 32.6% | $391.0M | $245.0M | $2.18 | $0.80 |
| FY 2025 | $11.04B | 31.9% | $1.60B | $992.0M | $8.75 | $3.15 |
| Q3 2025 | $2.82B | 33.7% | $386.0M | $245.0M | $2.16 | $0.80 |
| Q2 2025 | $2.76B | 34.2% | $438.0M | $282.0M | $2.47 | $0.80 |
| Q1 2025 | $2.65B | 32.5% | $346.0M | $220.0M | $1.94 | $0.75 |
| Q4 2024 | $2.62B | 32.7% | $361.0M | $222.0M | $1.95 | $0.75 |
| FY 2024 | $9.87B | 32.9% | $1.35B | $871.0M | $7.69 | $2.96 |
| Q3 2024 | $2.49B | 32.6% | $330.0M | $226.0M | $1.99 | $0.75 |
| Q2 2024 | $2.40B | 33.5% | $355.0M | $229.0M | $2.04 | $0.75 |
| Q1 2024 | $2.37B | 32.6% | $300.0M | $194.0M | $1.72 | $0.71 |
| Q4 2023 | $2.29B | 32.3% | $267.0M | $192.0M | $1.70 | $0.71 |
| FY 2023 | $9.25B | 33.2% | $1.26B | $854.0M | $7.52 | $2.79 |